In a filing, Ovid Therapeutics Inc revealed its President and COO ALEXANDER MARGARET A. acquired Company’s shares for reported $4971.0 on Jan 27 ’25. In the deal valued at $0.73 per share,6,810 shares were bought. As a result of this transaction, ALEXANDER MARGARET A. now holds 34,935 shares worth roughly $21659.7.
Then, LEVIN JEREMY M bought 18,248 shares, generating $50,364 in total proceeds. Upon buying the shares at $2.76, the CEO now owns 3,616,715 shares.
Oppenheimer downgraded its Ovid Therapeutics Inc [OVID] rating to a Perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who began to cover the stock in late April with a ‘”a Buy”‘ rating. H.C. Wainwright began covering OVID with “Buy” recommendation on April 29, 2024. Wedbush started covering the stock on April 05, 2024. It rated OVID as “an Outperform”.
Price Performance Review of OVID
On Friday, Ovid Therapeutics Inc [NASDAQ:OVID] saw its stock jump 8.91% to $0.62. Over the last five days, the stock has lost -4.37%. Ovid Therapeutics Inc shares have fallen nearly -33.87% since the year began. Nevertheless, the stocks have fallen -83.40% over the past one year. While a 52-week high of $3.79 was reached on 01/03/25, a 52-week low of $0.56 was recorded on 02/20/25. SMA at 50 days reached $0.8216, while 200 days put it at $1.2989.
Levels Of Support And Resistance For OVID Stock
The 24-hour chart illustrates a support level at 0.5735, which if violated will result in even more drops to 0.5294. On the upside, there is a resistance level at 0.6552. A further resistance level may holdings at 0.6928. The Relative Strength Index (RSI) on the 14-day chart is 38.63, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0464, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 64.16%. Stochastics %K at 16.02% indicates the stock is a buying.
The most recent change occurred on December 21, 2023 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $11 price target.
